Generate Investment Management Ltd Sells 17,005 Shares of Stryker Corporation $SYK

Key Points

• Generate Investment Management Ltd cut its Stryker stake by 55% in the first quarter, selling 17,005 shares and ending with 13,917 shares valued at about $4.57 million.
• Insider selling has been significant: VP Robert S. Fletcher and Director Ronda E. Stryker both sold shares recently, and insiders sold 323,264 shares worth roughly $100.7 million over the last 90 days.
• Stryker reported weaker-than-expected quarterly results, missing EPS and revenue estimates, while analysts still maintain a Moderate Buy consensus with an average price target of $395.33.

Generate Investment Management Ltd reduced its stake in Stryker Corporation (NYSE:SYK - Free Report) by 55.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 13,917 shares of the medical technology company's stock after selling 17,005 shares during the quarter. Generate Investment Management Ltd's holdings in Stryker were worth $4,573,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Sterling Investment Counsel LLC lifted its stake in Stryker by 5.4% in the first quarter. Sterling Investment Counsel LLC now owns 2,535 shares of the medical technology company's stock valued at $833,000 after purchasing an additional 131 shares during the last quarter. Brookstone Capital Management raised its stake in shares of Stryker by 10.1% in the first quarter. Brookstone Capital Management now owns 2,875 shares of the medical technology company's stock valued at $945,000 after buying an additional 264 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO raised its stake in shares of Stryker by 13.0% in the first quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 16,063 shares of the medical technology company's stock valued at $5,278,000 after buying an additional 1,850 shares during the period. Smith Salley Wealth Management lifted its position in shares of Stryker by 6.3% during the 1st quarter. Smith Salley Wealth Management now owns 5,468 shares of the medical technology company's stock valued at $1,797,000 after buying an additional 324 shares during the last quarter. Finally, Southern Capital Advisors LLC bought a new position in shares of Stryker during the 1st quarter worth $2,110,000. Institutional investors own 77.09% of the company's stock.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the company's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company's stock.

Stryker Stock Performance

Shares of SYK opened at $304.64 on Tuesday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The stock's 50-day simple moving average is $313.12 and its 200 day simple moving average is $341.06. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a market capitalization of $116.79 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $6.34 billion. During the same period in the previous year, the firm earned $2.84 EPS. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker's payout ratio is currently 40.74%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SYK. Weiss Ratings lowered Stryker from a "hold (c+)" rating to a "hold (c)" rating in a report on Monday, May 4th. Wells Fargo & Company cut their target price on shares of Stryker from $456.00 to $418.00 and set an "overweight" rating for the company in a research report on Friday, May 1st. Needham & Company LLC reduced their target price on shares of Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a research note on Friday, May 1st. Jefferies Financial Group reissued a "buy" rating and issued a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Finally, Truist Financial restated a "hold" rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.